ECR Pharmaceuticals : Zolpimist Oral Spray

February 2011 - ECR Pharmaceuticals Co., Inc., a subsidiary of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate. The Zolpimist Oral Spray unit contains 60 metered sprays and provides the flexibility of administering either a 5 or 10 mg dose of the zolpidem active ingredient. As with most prescription hypnotic agents, Zolpimist Oral Spray is federally classified as a CIV controlled substance. Zolpimist is only available by prescription.

Hi-Tech President and CEO David Seltzer indicated that "Zolpimist is a significant addition to ECR, our branded products subsidiary, and reflects our continuing commitment to build this segment of our business through the marketing of widely used, innovative products."

Steven Ratoff, the CEO of Novadel Pharma Inc., the developer of Zolpimist Oral Spray, said "we are pleased to have Zolpimist available in the U. S. marketplace." Over 79 million prescriptions are written annually in the US for sleep aid products... ECR Pharmaceuticals' Press Release - Novadel Pharma's Press Release -

Somnetics : New Transcend Sleep Apnea Therapy System Offers First Radical Advancement Since CPAPs Were Invented

January 10, 2011 - Wearable Therapy System Offers Hassle-Free Convenience, Unlimited Mobility and Freedom to Sleep Anywhere; Surpasses Any Conventional CPAP in Size, Design, and Technology – Designed to fit today’s active lifestyle, Transcend—which will be available for sale on January 21, 2011—is the first practical, wearable sleep apnea therapy system on the market that offers patients an innovative replacement to their old-fashion, cumbersome CPAP (continuous positive airway pressure) machines.

According to Ralph Germscheid, President of Somnetics, LLC, the maker of Transcend, “We’ve developed a completely new kind of therapy system. Transcend is FDA-approved and weighs approximately one pound. Its compact design, unique patent-pending heat moisture exchange technology, and portable power options make it ideal for travel and provide users with convenience and mobility not available from existing CPAP machines.”... Somnetics' Press Release -

Pico-Tesla : pilot study of Magneceutical® Therapy for fibromyalgia

Dec. 15, 2010 — Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

The study will be coordinated by Miguel Trevino, M.D., Medical Director, Innovative Research of West Florida, Clearwater, Fla. Dr. Trevino is certified to practice medicine by the American Board of Internal Medicine. Innovative Research of West Florida is a leading Clinical Research Site... Pico-Tesla's Press Release -

Nonin Medical : Next-generation wrist-worn pulse oximeter provides SpO2 monitoring flexibility and accuracy in ambulatory, sleep-study settings

Jan. 19, 2011 – Nonin Medical, Inc., the inventor of fingertip pulse oximetry and an innovator of noninvasive physiological monitoring solutions, announced the United States and Canadian launches of its WristOx2™, Model 3150 wrist-worn pulse oximeter.

The WristOx2, Model 3150 is a compact, wireless wrist-worn monitoring device that accurately monitors blood-oxygen saturation (SpO2) levels and pulse rate in patients undergoing ambulatory monitoring to screen for breathing disorders such as chronic obstructive pulmonary disease or sleep disorders such as obstructive sleep apnea. Engineered with Nonin’s PureSAT® SpO2 technology, the WristOx2, Model 3150 is proven clinically accurate in the widest range of clinical settings and challenging patient conditions such as motion and low perfusion. Featuring Bluetooth® wireless technology, a new ergonomic design and larger screen size, the WristOx2, Model 3150 is designed to increase patient comfort and ease of use... Nonin Medical's Press Release -

Philips strengthens home healthcare portfolio with acquisition of main business of medSage Technologies

January 6, 2011 - Royal Philips Electronics (AEX: PHI, NYSE: PHG) announced that it has acquired substantially all of the assets of medSage Technologies LLC, a leading provider of patient interaction and management applications (“medSage Technologies”). The acquisition will allow Philips to offer a web-based solution that enables home care providers to manage ongoing compliance and replenishment services for individuals under treatment for obstructive sleep apnea (OSA), diabetes, respiratory and other conditions. The acquired business will become part of the Sleep business within Philips Home Healthcare Solutions.

“We believe the need to manage chronic diseases by an aging population, coupled with health economics, will continue to drive a greater need for healthcare delivery at home,” said Steve Rusckowski, CEO of Philips Healthcare. “This acquisition is fully aligned to our strategy of providing home care providers with new opportunities to enhance their service offerings with an effective and cost-efficient application.” Philips' Press Release -